Description
Relvar Ellipta 100/25mcg 30 treats asthma in adults and adolescents aged 12 years and older. The drugs is appropriate when there is a need for a combination medicinal product. Also, Relvar Ellipta 100/25mcg 30 helps patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting beta2-agonists. The drug as well treats patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.